712 related articles for article (PubMed ID: 10069876)
1. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group.
FitzGerald JM; Chapman KR; Della Cioppa G; Stubbing D; Fairbarn MS; Till MD; Brambilla R
J Allergy Clin Immunol; 1999 Mar; 103(3 Pt 1):427-35. PubMed ID: 10069876
[TBL] [Abstract][Full Text] [Related]
2. Effect of long-term salmeterol therapy compared with as-needed albuterol use on airway hyperresponsiveness.
Rosenthal RR; Busse WW; Kemp JP; Baker JW; Kalberg C; Emmett A; Rickard KA
Chest; 1999 Sep; 116(3):595-602. PubMed ID: 10492259
[TBL] [Abstract][Full Text] [Related]
3. Comparison between formoterol 12 microg b.i.d. and on-demand salbutamol in moderate persistent asthma.
Molimard M; Bourcereau J; Le Gros V; Bourdeix I; Leynadier F; Duroux P;
Respir Med; 2001 Jan; 95(1):64-70. PubMed ID: 11207020
[TBL] [Abstract][Full Text] [Related]
4. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists.
van der Woude HJ; Winter TH; Aalbers R
Thorax; 2001 Jul; 56(7):529-35. PubMed ID: 11413351
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the efficacy of formoterol and salmeterol in patients with reversible obstructive airway disease: a multicenter, randomized, open-label trial.
Condemi JJ
Clin Ther; 2001 Sep; 23(9):1529-41. PubMed ID: 11589265
[TBL] [Abstract][Full Text] [Related]
6. A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol.
Lipworth BJ; Aziz I
J Allergy Clin Immunol; 1999 Jan; 103(1 Pt 1):88-92. PubMed ID: 9893190
[TBL] [Abstract][Full Text] [Related]
7. Protective effect of budesonide/formoterol compared with formoterol, salbutamol and placebo on repeated provocations with inhaled AMP in patients with asthma: a randomised, double-blind, cross-over study.
Aalbers R; Boorsma M; van der Woude HJ; Jonkers RE
Respir Res; 2010 May; 11(1):66. PubMed ID: 20509942
[TBL] [Abstract][Full Text] [Related]
8. Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators.
van der Molen T; Postma DS; Turner MO; Jong BM; Malo JL; Chapman K; Grossman R; de Graaff CS; Riemersma RA; Sears MR
Thorax; 1997 Jun; 52(6):535-9. PubMed ID: 9227720
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of salmeterol and formoterol in patients with severe asthma.
Nightingale JA; Rogers DF; Barnes PJ
Chest; 2002 May; 121(5):1401-6. PubMed ID: 12006420
[TBL] [Abstract][Full Text] [Related]
10. Effects of treatment with formoterol on bronchoprotection against methacholine.
Lipworth B; Tan S; Devlin M; Aiken T; Baker R; Hendrick D
Am J Med; 1998 May; 104(5):431-8. PubMed ID: 9626025
[TBL] [Abstract][Full Text] [Related]
11. Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma.
Aziz I; Hall IP; McFarlane LC; Lipworth BJ
J Allergy Clin Immunol; 1998 Mar; 101(3):337-41. PubMed ID: 9525449
[TBL] [Abstract][Full Text] [Related]
12. A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler.
Bensch G; Lapidus RJ; Levine BE; Lumry W; Yegen U; Kiselev P; Della Cioppa G
Ann Allergy Asthma Immunol; 2001 Jan; 86(1):19-27. PubMed ID: 11206232
[TBL] [Abstract][Full Text] [Related]
13. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
FitzGerald JM; Boulet LP; Follows RM
Clin Ther; 2005 Apr; 27(4):393-406. PubMed ID: 15922813
[TBL] [Abstract][Full Text] [Related]
14. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol.
Kalra S; Swystun VA; Bhagat R; Cockcroft DW
Chest; 1996 Apr; 109(4):953-6. PubMed ID: 8635376
[TBL] [Abstract][Full Text] [Related]
15. Reduced dose salbutamol in comparison with standard dosage for symptom relief in asthma.
Yates DH; Peters MJ; Keatings V; Thomas PS; Barnes PJ
Eur Respir J; 1995 Nov; 8(11):1847-51. PubMed ID: 8620950
[TBL] [Abstract][Full Text] [Related]
16. Is the increase in bronchial responsiveness or FEV1 shortly after cessation of beta2-agonists reflecting a real deterioration of the disease in allergic asthmatic patients? A comparison between short-acting and long-acting beta2-agonists.
van Schayck CP; Cloosterman SG; Bijl-Hofland ID; van den Hoogen H; Folgering HT; van Weel C
Respir Med; 2002 Mar; 96(3):155-62. PubMed ID: 11908511
[TBL] [Abstract][Full Text] [Related]
17. Long-acting beta(2)-agonists in management of childhood asthma: A critical review of the literature.
Bisgaard H
Pediatr Pulmonol; 2000 Mar; 29(3):221-34. PubMed ID: 10686044
[TBL] [Abstract][Full Text] [Related]
18. A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma.
Kesten S; Chapman KR; Broder I; Cartier A; Hyland RH; Knight A; Malo JL; Mazza JA; Moote DW; Small P
Am Rev Respir Dis; 1991 Sep; 144(3 Pt 1):622-5. PubMed ID: 1892303
[TBL] [Abstract][Full Text] [Related]
19. Airway subsensitivity with long-acting beta 2-agonists. Is there cause for concern?
Lipworth BJ
Drug Saf; 1997 May; 16(5):295-308. PubMed ID: 9187530
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, single-dose, crossover clinical trial of the onset and duration of protection from exercise-induced bronchoconstriction by formoterol and albuterol.
Shapiro GS; Yegen U; Xiang J; Kottakis J; Della Cioppa G
Clin Ther; 2002 Dec; 24(12):2077-87. PubMed ID: 12581546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
